# A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

> **NCT03193190** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 341 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Nab-Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil
- **DRUG:** Atezolizumab
- **DRUG:** Cobimetinib
- **DRUG:** PEGPH20
- **DRUG:** BL-8040
- **DRUG:** Selicrelumab
- **DRUG:** Bevacizumab
- **DRUG:** RO6874281
- **DRUG:** AB928
- **DRUG:** Tiragolumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03193190
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-05
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193190, "A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03193190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*